Cell retargeting by bispecific monoclonal antibodies: Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma

P. Nisticò, R. Mortarini, L. B. De Monte, A. Mazzocchi, M. Mariani, F. Malavasi, G. Parmiani, P. G. Natali, A. Anichini

Research output: Contribution to journalArticle

Abstract

Intratumor heterogeneity for susceptibility to cytotoxic T lymphocytes (CTL)-mediated lysis represents a major obstacle to cancer adoptive immunotherapy. To overcome the heterogeneity observed in terms of susceptibility of target cells to cell-mediated lysis, in this study we used two purified bispecific monoclonal antibodies (bsmAbs) that recognize molecules expressed by cytotoxic effector cells (CD3 and IgG Fc receptorial molecules), as well as one high molecular weight melanoma-associated antigen (HMW-MAA). The ability of these reagents to enhance or induce a relevant in vitro cytotoxic activity by a CTL clone (CTL 49) isolated from PBL of a melanoma patient was tested on a large panel of autologous and allogeneic melanoma cell lines and clones. Functional studies revealed that the CTL 49 clone lysed all the HMW-MAA+ tumor lines in the presence of bsmAbs and that these reagents affected the target lysis in a cooperative fashion. The effectiveness of bsmAbs in overcoming the heterogeneous susceptibility of human melanoma cells to cell-mediated lysis may find practical implications in cancer adoptive immunotherapy.

Original languageEnglish
Pages (from-to)1093-1099
Number of pages7
JournalJournal of Clinical Investigation
Volume90
Issue number3
Publication statusPublished - 1992

Keywords

  • Antibody bridging
  • Autologous tumor
  • Cytotoxic activity
  • Melanoma-associated antigen
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cell retargeting by bispecific monoclonal antibodies: Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma'. Together they form a unique fingerprint.

  • Cite this